Development of a humanised antibody for treatment of cancer and stroke

开发用于治疗癌症和中风的人源化抗体

• 批准号: nhmrc : 1038334
• 负责人: Prof Andrew Scott
• 金额: $ 26.68万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-humanised-antibody-cancer-stroke/111125
• 关键词: Development; humanised; antibody; treatment; cancer

The protein PDGF-CC has a critical role in blood vessel development, and is implicated in the development of cancer, and the debilitating consequences of acute stroke. Researchers in the Ludwig Institute for Cancer Research have developed novel anti-PDGF-CC antibodies. The research program proposed will generate data and clinical reagents that will enable a lead candidate anti-PDGF-CC antibody to be commercialised, and ultimately evaluated clinically in cancer and stroke patients.

PDGF-CC蛋白在血管发育中起着关键作用，并与癌症的发展和急性中风的衰弱后果有关。路德维希癌症研究所的研究人员开发了一种新的抗pdgf - cc抗体。拟议的研究计划将产生数据和临床试剂，使抗pdgf - cc抗体的主要候选抗体商业化，并最终在癌症和中风患者中进行临床评估。